Natural History Study of Patients With Neurofibromatosis Type 2

Abroad (travel likely)Recruiting

Conditions

Neurofibromatosis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Study leads

Prashant Chittiboina, M.D.
Principal Investigator
National Institute of Neurological Disorders and Stroke (NINDS)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Clinical and Demographic Characteristics of Adult p Atients With NEurofibromatosis in RUSsia

Neurofibromatosis

Abroad (travel likely)Recruiting

Arkhangelsk, Russia · Chelyabinsk, Russia

Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)

Neurofibromatosis 1 · Plexiform Neurofibromas

Abroad (travel likely)Recruiting

Washington D.C., United States · Chicago, United States

Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas

Neurofibromatosis 1

Abroad (travel likely)RecruitingPHASE1, PHASE2

Bethesda, United States

Tailoring an Online Platform to Promote Evidence-Based Care for Adults With Neurofibromatosis 1 and Low Health Literacy

Neurofibromatosis 1

Abroad (travel likely)Recruiting

Boston, United States